AI-generated from publicly available materials.Neopharma Technologies has reached a significant milestone by securing ISO/IEC 42001:2023 certification for its NEOVAULT® diagnostic platform, enhancing its commitment to responsible AI management.
This certification validates Neopharma's Artificial Intelligence Management System (AIMS), covering the entire lifecycle of its NEOVAULT® and myNEO® software solutions. It establishes a recognized framework for the governance of AI technologies, ensuring they are developed, deployed, and maintained responsibly. This achievement complements Neopharma's existing compliance with other standards like ISO/IEC 27001 and GDPR, reinforcing its strategy to create a reliable digital infrastructure for diagnostic and healthcare environments worldwide.
Shaun Melville, Executive Director, emphasized that this certification is crucial for the global advancement of NEOVAULT®. He noted that effective governance of AI technologies is essential as the platform integrates diagnostic solutions and workflows at scale. Similarly, Gajenddra Raj, Chief Technology Officer, highlighted that the certification's comprehensive scope ensures that security, privacy, and accountability are integral to the platform's architecture.
NEOVAULT® aims to serve as a versatile diagnostics platform that connects various diagnostic technologies and workflows within a secure digital framework. While its initial focus is on workplace health and drug testing, the platform is designed for future expansion into broader health diagnostics, signifying its potential impact on the healthcare landscape.